. Author manuscript; available in PMC: 2015 Aug 1.

Published in final edited form as: Kidney Int. 2014 Aug 6;87(2):332–342. doi: 10.1038/ki.2014.270

Table 1.

APOL1 genotypes of individuals with interferon-associated FSGS.

	Race/ Ethnicity	Gender/ Age	Indication	Interferon type	Scr (mg/dL)	Upr (g/day)	APOL1 Genotype
1	Black	46F	HCV	Alpha	3.2/1.2	10.0/3.6	G1/G2
2	Hispanic	64M	HCV	Alpha	1.5/1.0	4.5/neg	G2/G2
3	Black	69M	HCV	Alpha	6.9/5.6	3.3/NA	G2/G2
4	Black	36F	Melanoma	Alpha	1.4/1.0	27.0/4.5	G1/G2
5	Black	33F	MS	Beta	2.6/1.7	1.9/0.5	G1/G2
6	Black	37F	MS	Beta	2.3/1.2	2.4/1.4	G1/G2
7	Black	67M	Pulm. Fibr.	Gamma	3.5/2.1	4.0/0.65	G1/G2

APOL1 genotyping for a case series originally reported in Markowitz et al. (reference 16). In addition to APOL1 genotype, the serum creatinine and urine protein levels are shown while receiving and after discontinuing interferon. Abbreviations: hepatitis C virus (HCV), multiple sclerosis (MS), pulmonary fibrosis (pulm. fibr.), serum creatinine (Scr), milligrams per deciliter (mg/dL), urine protein in grams per day (Upr). The G1 allele is defined by two amino acid substitutions: S342G and I384M. The G2 allele is defined by in-frame deletion of amino acids 388N and 389Y.